Compare AIIA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIIA | SLS |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.5M | 208.0M |
| IPO Year | 2025 | N/A |
| Metric | AIIA | SLS |
|---|---|---|
| Price | $10.00 | $3.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 52.2K | ★ 7.6M |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $0.95 |
| 52 Week High | $10.24 | $5.18 |
| Indicator | AIIA | SLS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.49 |
| Support Level | N/A | $3.49 |
| Resistance Level | N/A | $4.20 |
| Average True Range (ATR) | 0.00 | 0.39 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 0.00 | 9.96 |
AI Infrastructure Acquisition Corp is a blank check company.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.